TrialCancer communications (London, England)2026
Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial.
Fengpeng Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.